GSE218378 PBX1 overexpression HCT 116 1 v 0 human up (Gene Set)

Analyze

Playbook Workflow Builder
Playbook Workflow Builder: Gene Set Enrichment

Perform Gene Set Enrichment with this gene set against Common Fund program's gene sets, identifying significant overlaps using a pre-built PWB workflow. Run the workflow with GSE218378_PBX1 overexpression_HCT 116_1_v_0_human_up.

GeneSetCart
GeneSetCart

GeneSetCart helps you to fetch gene sets from various data sources, augment, combine with set operations, visualize and analyze these gene sets in a single session. Start a new session with GSE218378_PBX1 overexpression_HCT 116_1_v_0_human_up.

CFDE-GSE
CFDE Gene Set Enrichment (GSE)

CFDE-GSE illuminates connections between the input gene set and various CF gene sets that overlap with the queried gene set. Query CFDE-GSE with GSE218378_PBX1 overexpression_HCT 116_1_v_0_human_up.

Playbook Workflow Builder
Playbook Workflow Builder

The Playbook Workflow Builder helps you interactively construct workflows leveraging CFDE APIs without code. Start a new workflow with GSE218378_PBX1 overexpression_HCT 116_1_v_0_human_up.

Results found

Linked to

 

Label

Description

 

Gene

growth arrest specific 5

Gene

small nucleolar RNA host gene 29

Gene

small nucleolar RNA host gene 5

Gene

non-coding RNA activated by DNA damage

Gene

OIP5 antisense RNA 1

Gene

ZNFX1 antisense RNA 1

Gene

general transcription factor IIi pseudogene 4

Gene

CASTOR family member 3, pseudogene

Gene

BAIAP2 divergent transcript

Gene

HERC2 pseudogene 2

  • Gene

    growth arrest specific 5


  • Gene

    small nucleolar RNA host gene 29


  • Gene

    small nucleolar RNA host gene 5


  • Gene

    non-coding RNA activated by DNA damage


  • Gene

    OIP5 antisense RNA 1


  • Gene

    ZNFX1 antisense RNA 1


  • Gene

    general transcription factor IIi pseudogene 4


  • Gene

    CASTOR family member 3, pseudogene


  • Gene

    BAIAP2 divergent transcript


  • Gene

    HERC2 pseudogene 2

  • DISPLAY PER PAGE
    This repository is under review for potential modification in compliance with Administration directives.